NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-0318720... ( SOPHIA ANTIPOLIS France Jan. 3 /-...)

NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan

Date:1/3/2008

SOPHIA ANTIPOLIS, France, Jan. 3 /PRNewswire/ -- NicOx S.A. (Euronext Paris: COX) today announced that Pfizer Inc (NYSE: PFE) has initiated a dose-ranging phase 2 clinical study for PF-03187207 in Japan. PF-03187207 is a new experimental medicine for the treatment of glaucoma, which is currently in an ongoing phase 2 proof-of-concept study in the United States (see press releases of March 28 and 29, 2007). Glaucoma and ocular hypertension are a group of severe eye diseases that can lead to blindness and this new Japanese study will compare the safety and efficacy of PF-03187207 to Xalatan(R) (latanoprost) in Japanese patients with these conditions. Xalatan(R) is a proprietary Pfizer product and the leader in worldwide glaucoma sales, with approximately $1.5 billion of franchise sales in 2006.

PF-03187207 is the lead development compound generated under the August 2004 collaboration agreement between Pfizer and NicOx, which focuses on the research and development of nitric oxide-donating prostaglandin F2-alpha analogs for the treatment of glaucoma (see NOTE).

Maarten Beekman, Vice President of Clinical Development at NicOx, said: "We believe the initiation of this separate Japanese study for PF-03187207 highlights Pfizer's determination to rapidly advance this clinical program towards coordinated regulatory filing in the world's major pharmaceutical markets. Preclinical results have suggested that NicOx' technology has the potential to deliver improved treatments for glaucoma and we look forward to the results of the ongoing proof-of-concept phase 2 study for PF-03187207 in the United States."

Design and rationale for the study

The first clinical study for PF-03187207, initiated in March 2007 in the United States
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947

Post Your Comments:

NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-0318720...( SOPHIA ANTIPOLIS France Jan. 3 /-...),Health